switching between glp 1 agonists chart Outcomes in GLP-1 RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy Schematic illustration of monoagonists, dual
Description
Diabetes Care 2018;41:26692701 [DOI] [PMC free article] [PubMed] [Google Scholar] 5.Buse JB, Wexler DJ, Tsapas A, et al
Ruggiero R, Mascolo A, Spezzaferri A, Carpentieri C, Torella D, Sportiello L, et al
GLP-1 lawsuit claims center on allegations that manufacturers of medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 receptor agonist drugs failed to adequately warn patients and physicians about serious health risks associated with these medications
However, many of these drugs were associated with unexpected adverse effects, such as nausea, aversion, valvular heart disease, and even suicidal tendencies, leading to the discontinuation of most of their development
Type 3 cytokines IL-17A and IL-22 drive TGF--dependent liver fibrosis
